A 28.8-day half-life is not a minor pharmacokinetic footnote — it is the structural argument for everything RESP-X is trying to do. Quarterly dosing intervals in a chronically colonized respiratory population would represent a fundamental departure from the inhaled antibiotic regimens that currently define this space, and Infex Therapeutics‘ Phase IIa data, presented at ATS 2026, make that case more concretely than any earlier-stage readout could.
The trial was small, single-site, and conducted at Liverpool University Hospitals — two dose cohorts, 6 mg/kg and 10 mg/kg, in non-cystic fibrosis bronchiectasis patients colonized with Pseudomonas aeruginosa. The primary objective was safety, and RESP-X cleared it without equivocation: no severe or life-threatening treatment-emergent adverse events attributed to the drug, zero infusion reactions, no patient withdrawals, no anti-drug antibodies detected at any timepoint. That immunogenicity profile matters specifically because RESP-X is a humanized IgG4 monoclonal targeting PcrV — a virulence protein on the Type III Secretion System — not a bactericidal agent. ADAs in a repeat-dosing chronic disease setting can erode both efficacy and tolerability over time; their absence here removes what would otherwise be a serious development risk. Bronchoalveolar lavage confirmed drug reached epithelial lining fluid at 48 hours post-dose across all treated patients, and every Pa isolate collected encoded the PcrV target — complete target coverage, not partial.
The efficacy signal is where the data get genuinely interesting and genuinely preliminary in equal measure. Pa-positive patients experienced fewer exacerbations from day 1 through day 180 compared with the prior 12 months, but the p-value landed at 0.08 — directionally real, statistically inconclusive. That is exactly what a Phase IIa exploratory endpoint should look like: enough signal to justify the next study, not enough to claim victory. Infex has been appropriately measured in how it characterizes this. The 10 mg/kg dose provides serum coverage over the PK/PD target necessary to sustain that three-month dosing interval, which aligns with the Phase I healthy volunteer data — no surprises between populations, which is the more reassuring finding than the number itself.
The pivotal design question now is exacerbation rate as a primary endpoint in the Phase III-equivalent study. Regulatory precedent in bronchiectasis is thin and contested; how Infex negotiates endpoint selection with EMA and FDA will determine whether this program’s timeline is measured in years or in a decade.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
